Aptadel Therapeutics<\/strong><\/a>, focused on developing aptamers linked to cancer treatments to obtain more effective therapies with fewer adverse effects.<\/p>\n <\/p>\n
Aptamer alone already has an antitumor effect<\/h3>\n
Apart from acting as a targeted drug delivery platform, the research team found that the aptamer alone already had an antitumor effect.<\/p>\n
The target receptor, to which the new molecule binds, plays a very important role in tumor aggressiveness. The researchers found that the aptamer binding reduce metastatic capacity of cells in culture<\/strong>. Additionally, in a mouse model of Ewing’s Sarcoma, a bone cancer that affects children, aptamer administration slowed tumor growth and significantly reduced the occurrence of metastases.<\/p>\n“We could say that aptamer alone already has a preventive effect, it slows down the evolution of cancer<\/em> -says Dr. Mart\u00ednez Tirado<\/strong>-. Alone, it could help us turn cancer into a chronic disease, and at the same time, conjugated with anti-cancer drugs, it could be even more powerful<\/em>.”<\/p>\n <\/p>\n
Double selection to obtain a more affinity aptamer<\/h3>\n
The researchers have achieved this high-affinity aptamer thanks to an innovative double-selection method that considered both its affinity for the purified receptor and the ability of tumor cells to internalize it.<\/p>\n
Dr. Paloma Giangrande<\/strong> from the University of Iowa points out that “this has allowed us to select the aptamers that bind more strongly to the receptor, but also, cell assays have shown us the ones that act at physiological level, those that attached to the three-dimensional structure of the receptor and that the tumor cells could internalize<\/em>\u201d.<\/p>\nAll this has been possible thanks to the support of the Alba P\u00e9rez Foundation, the Ministry of Science and Innovation, and the grants of the Spanish Association Against Cancer Ideas Semilla AECC and AECC Innova.<\/p>\n
<\/p>\n
<\/p>\n
The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.<\/em><\/p>\nIDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"It is an aptamer, a small nucleic acid molecule that specifically recognizes a receptor highly expressed in tumor cells of breast cancer, sarcoma, melanoma, and colon cancer, among others. The new molecule could be linked to cancer treatments and used as a platform for localized drug delivery that reduces side effects.<\/p>\n","protected":false},"author":8,"featured_media":22678,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[180,264,237],"tags":[],"class_list":["post-22676","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell","category-sarcoma"],"publishpress_future_action":{"enabled":false,"date":"2025-04-09 22:42:42","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/22676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=22676"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/22676\/revisions"}],"predecessor-version":[{"id":22679,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/22676\/revisions\/22679"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media\/22678"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=22676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/categories?post=22676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/tags?post=22676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}